Literature DB >> 19389068

Comparative pharmacodynamic interaction analysis of triple combinations of caspofungin and voriconazole or ravuconazole with subinhibitory concentrations of amphotericin B against Aspergillus spp.

Joanne P Demchok1, Joseph Meletiadis, Emmanuel Roilides, Thomas J Walsh.   

Abstract

Triple combination therapy with an antifungal triazole, echinocandin and amphotericin B (AmB) is used in some centres to treat refractory aspergillosis. The objective of this study was to investigate the effect of subinhibitory concentrations of AmB on the double combinations of caspofungin (CAS) + voriconazole (VOR) or ravuconazole (RAV) against Aspergillus fumigatus, Aspergillus flavus and Aspergillus terreus. Isolates were studied in triplicate against CAS/VOR and CAS/RAV combinations by chequerboard broth microdilution. AmB was added to each double combination at concentrations of 0, 0.1 and 0.2 microg ml(-1). The fractional inhibitory concentration (FIC) index was calculated for the double and triple combinations. Comparative analysis was performed by repeated measures analysis followed by Dunnett's post-test. The double combinations of CAS/RAV and CAS/VOR were synergistic or additive in most conditions. Addition of AmB to the double combinations resulted in increased FIC indices for A. fumigatus and A. flavus. By contrast, AmB increased the synergism of the double combinations decreasing FIC indices for A. terreus (P < 0.05). RAV and VOR displayed similar synergistic activity with CAS. The addition of sub-inhibitory amphotericin B concentrations reduced but did not eliminate the synergistic interaction between the echinocandin and triazole against A. fumigatus and A. flavus, while it increased the synergy against A. terreus.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19389068      PMCID: PMC6999699          DOI: 10.1111/j.1439-0507.2009.01700.x

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  21 in total

Review 1.  Combination antifungal therapy: what can and should we expect?

Authors:  M D Johnson; J R Perfect
Journal:  Bone Marrow Transplant       Date:  2007-06-11       Impact factor: 5.483

2.  Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis.

Authors:  Karl V Clemons; Marife Espiritu; Rachana Parmar; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

Review 3.  Use of amphotericin B with azole antifungal drugs: what are we doing?

Authors:  A M Sugar
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

4.  Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model.

Authors:  Joseph Meletiadis; Theodouli Stergiopoulou; Elizabeth M O'Shaughnessy; Joanne Peter; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2007-03-26       Impact factor: 5.191

5.  Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis.

Authors:  William R Kirkpatrick; Sofia Perea; Brent J Coco; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

6.  Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies.

Authors:  Dimitrios P Kontoyiannis; Ray Hachem; Russell E Lewis; Gustavo A Rivero; Harrys A Torres; John Thornby; Richard Champlin; Hagop Kantarjian; Gerald P Bodey; Issam I Raad
Journal:  Cancer       Date:  2003-07-15       Impact factor: 6.860

7.  Amphotericin B refractory aspergillosis after itraconazole: evidence for significant antagonism.

Authors:  A Schaffner; A Böhler
Journal:  Mycoses       Date:  1993 Nov-Dec       Impact factor: 4.377

8.  In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp.

Authors:  Sofia Perea; Gloria Gonzalez; Annette W Fothergill; William R Kirkpatrick; Michael G Rinaldi; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

9.  In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus.

Authors:  Eric Dannaoui; Olivier Lortholary; Françoise Dromer
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

10.  Antagonistic interactions between azoles and amphotericin B with yeasts depend on azole lipophilia for special test conditions in vitro.

Authors:  M Scheven; F Schwegler
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

View more
  5 in total

1.  Current role of echinocandins in the management of invasive aspergillosis.

Authors:  Małgorzata Mikulska; Claudio Viscoli
Journal:  Curr Infect Dis Rep       Date:  2011-12       Impact factor: 3.725

Review 2.  Echinocandin antifungal drugs in fungal infections: a comparison.

Authors:  Sharon C-A Chen; Monica A Slavin; Tania C Sorrell
Journal:  Drugs       Date:  2011-01-01       Impact factor: 9.546

3.  In Vitro Triple Combination of Antifungal Drugs against Clinical Scopulariopsis and Microascus Species.

Authors:  Limin Yao; Zhe Wan; Ruoyu Li; Jin Yu
Journal:  Antimicrob Agents Chemother       Date:  2015-05-26       Impact factor: 5.191

4.  In vitro interaction between alginate lyase and amphotericin B against Aspergillus fumigatus biofilm determined by different methods.

Authors:  Francesca Bugli; Brunella Posteraro; Massimiliano Papi; Riccardo Torelli; Alessandro Maiorana; Francesco Paroni Sterbini; Patrizia Posteraro; Maurizio Sanguinetti; Marco De Spirito
Journal:  Antimicrob Agents Chemother       Date:  2012-12-21       Impact factor: 5.191

5.  When more is less: Emergent suppressive interactions in three-drug combinations.

Authors:  Casey Beppler; Elif Tekin; Cynthia White; Zhiyuan Mao; Jeffrey H Miller; Robert Damoiseaux; Van M Savage; Pamela J Yeh
Journal:  BMC Microbiol       Date:  2017-05-06       Impact factor: 3.605

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.